Diurnal Group PLC represents a set of core values and corporate philosophy that drive its operations. The company believes in integrity, transparency, and accountability in all its endeavors. Diurnal Group PLC is dedicated to delivering innovative and effective solutions in the field of hormone therapeutics, aiming to improve the lives of patients suffering from endocrine disorders. With a strong emphasis on research and development, the company strives to maintain a high level of scientific excellence and continuously evolve its product portfolio. Diurnal Group PLC's commitment to patient-centricity and collaboration with healthcare professionals reflects its vision of providing optimal and accessible treatments worldwide.

Diurnal Group PLC is primarily present in the United Kingdom and Europe.

Diurnal Group PLC has achieved several significant milestones. Firstly, the company successfully received marketing authorization in Europe for its hormone replacement therapy, Alkindi. This milestone allowed Diurnal Group PLC to launch Alkindi and provide treatment for pediatric patients with adrenal insufficiency. Additionally, the company achieved a positive outcome in the European decentralized procedure for its product, Chronocort, which is used to treat adrenal insufficiency in adults. These milestones demonstrate Diurnal Group PLC's successful development and commercialization of innovative therapies that address unmet medical needs in endocrinology.

Diurnal Group PLC is a pharmaceutical company founded in 2004 and headquartered in the United Kingdom. It specializes in developing and commercializing hormone-based therapeutics to treat rare and chronic endocrine diseases. Diurnal Group PLC focuses on innovative oral formulations, aiming to provide patients with convenient and effective treatment options. With a strong emphasis on research and development, the company has successfully brought several products to market, addressing significant unmet medical needs. Diurnal Group PLC continues to expand its portfolio and collaborate with healthcare professionals, aiming to improve the quality of life for patients suffering from hormonal disorders.

The main competitors of Diurnal Group PLC in the market include pharmaceutical companies that operate in the field of specialty pharmaceuticals and endocrinology. Some key competitors of Diurnal Group PLC are pharmaceutical companies such as Novartis AG, Sanofi SA, and Pfizer Inc., among others. These companies also focus on developing and commercializing drugs in areas related to endocrinology, allowing for a competitive environment within the market.

Diurnal Group PLC primarily operates in the pharmaceutical industry.

Diurnal Group PLC operates in the pharmaceutical industry, specializing in rare and chronic endocrine diseases. The company focuses on developing and commercializing innovative hormone-based therapies. Diurnal Group PLC aims to provide long-acting, low-dose, and convenient treatment options to improve patients' quality of life. With a strong commitment to research and development, the company combines its expertise in endocrinology, formulation science, and regulatory affairs to bring novel treatments to market. With a focus on unmet medical needs, Diurnal Group PLC strives to make a significant impact in the field of endocrinology.

Diurnal Group P/E suhe on −2,58.

Diurnal Group KUV on 2,61.

AlleAktien kvaliteediskoor ettevõttele Diurnal Group on 4/10.

oodatud Diurnal Group käive on 17,70 mln. GBP.

oodatud Diurnal Group kasum on −17,88 mln. GBP.

The Diurnal Group PLC is a specialized pharmaceutical company based in the UK, focusing on the development and marketing of hormone preparations for the treatment of rare and chronic diseases and disorders. The company is divided into different areas: - Endocrinology: This is Diurnal's main area, focusing on the treatment of hormonal disorders. The most well-known product in this area is Alkindi, a cortisone preparation for the treatment of adrenal insufficiencies in children. In addition to Alkindi, the company also offers Chronocort, which is used to treat adult patients with Addison's disease, and Infacort, which is specifically developed for infants and young children. - Chronobiology: This area focuses on the development of drugs targeting the sleep-wake cycle and other periodic rhythms of the human body. In this area, the company has already developed two products; Chronocort to alleviate symptoms of Cushing's syndrome, and Infacort, intended for the treatment of adrenal insufficiency in newborns. - Metabolism: Diurnal aims to develop new treatment options for patients with metabolism disorders such as hypoglycemia and hyperammonemia. The company works closely with clinicians and other medical professionals to understand and meet the needs of patients. Diurnal's goal is to offer innovative drugs that can improve patients' lives and alleviate their symptoms. Diurnal also utilizes state-of-the-art technologies and research findings to enhance the quality and efficacy of its products. The company has the potential to make decades-long contributions through its broad range of activities in various areas of endocrinology. Overall, the company's business model is focused on addressing the needs of patients with rare diseases. Diurnal is working hard to develop novel medications for the treatment of metabolism and hormone disorders that have the potential to have a life-changing impact on many people. The Diurnal Group PLC has set its goal to develop and bring to market new medications through long-term research and partnerships with clinicians and patient groups. Through this approach and their groundbreaking innovations, they have gained a reputation as a pioneer in the field of endocrinology.

Diurnal Group maksab dividendi 0 GBP, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Diurnal Group jaoks arvutada või ettevõte ei maksa dividende välja.

Diurnal Group ISIN on GB00BDB6Q760.

Diurnal Group tähis on DNL.L.

Viimase 12 kuu jooksul maksis Diurnal Group dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Diurnal Group tõenäoliselt dividendi summas 0 GBP.

Diurnal Group praegune dividenditootlus on .

Diurnal Group maksab kvartaalset dividendi. See makstakse välja kuudel .

Diurnal Group maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 GBP. See vastab dividenditootlusele 0 %.

Diurnal Group on liigitatud sektorisse 'Tervis'.

Viimase Diurnal Group dividendide saamiseks 9.11.2024 suuruses 0 GBP pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 9.11.2024.

Viimane dividendimakse toimus 9.11.2024.

Aastal 2023 maksis Diurnal Group 0 GBP dividende.

Diurnal Group dividendid makstakse välja GBP.